SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival.
Mohelnikova-Duchonova B, Strouhal O, Hughes DJ, Holcatova I, Oliverius M, Kala Z, Campa D, Rizzato C, Canzian F, Pezzilli R, Talar-Wojnarowska R, Malecka-Panas E, Sperti C, Federico Zambon C, Pedrazzoli S, Fogar P, Milanetto AC, Capurso G, Delle Fave G, Valente R, Gazouli M, Malleo G, Teresa Lawlor R, Strobel O, Hackert T, Giese N, Vodicka P, Vodickova L, Landi S, Tavano F, Gioffreda D, Piepoli A, Pazienza V, Mambrini A, Pedata M, Cantore M, Bambi F, Ermini S, Funel N, Lemstrova R, Soucek P.
Mohelnikova-Duchonova B, et al. Among authors: kala z.
Sci Rep. 2017 Mar 8;7:43812. doi: 10.1038/srep43812.
Sci Rep. 2017.
PMID: 28272475
Free PMC article.